Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu
Articles > Article · 2014
Authors: Zengel, Baha, Alacacıoglu, Ahmet, AYŞE YAĞCI, Postacı, Hakan, Kavak, Ozgur, Galip, Ali, Erhan GÖKMEN
DergiPark (Istanbul University), International, 2014
Summary
Gastrointestinal stromal tumors are characterized by the expression of CD34 and c-kit (CD117) and represent the most common mesenchymal malignancy of the gastrointestinal tract.Imatinib mesylate is small molecule tyrosine kinase inhibitor that suppresses transmembrane receptor c-kit products.Clinical studies for metastatic and inoperabl GISTs have demonstrated partial response rate ranging from 40% to 69% in patients treated with imatinib mesylate.But complete response is rare.We present a 46 year old man patient with unresectable gastrointestinal stromal tumor that has histopatologically proven complete response to imatinib mesylate therapy.